AUS
NZ
UK
CA
USA
IND
_07_17_2023_11_54_00_546595.jpg)
Patrys Limited (ASX:PAB) is advancing a proprietary injectable formulation of quetiapine, a commonly prescribed antipsychotic, aimed at treating delirium in intensive care units and aged care environments. This reformulated drug promises a quicker onset and a more cost-effective development route compared to traditional drug discovery, targeting a serviceable addressable market exceeding US$2 billion annually. The company anticipates a 3–5 year development period utilizing the FDA 505(b)(2) regulatory pathway, with projected costs between US$20 million and US$30 million.
Key Points
- Patrys Limited (ASX:PAB) is creating a proprietary injectable quetiapine formulation for delirium management in ICU and aged care settings.
- The injectable version delivers immediate onset, unlike oral quetiapine which requires 1–2 hours to take effect.
- Development is projected to take 3–5 years, costing approximately US$20–30 million, significantly less than the US$1.2 billion typical for new drug discovery.
- Patrys holds provisional patent protection in Australia without trailing obligations and filed a new provisional patent application in 2026 for the reformulated product.
- The global addressable market for delirium treatment is estimated at over US$2 billion annually.
- The board includes seasoned directors with expertise in biotech commercialisation, ASX governance, capital markets, and clinical trial management.
Delirium Overview: A Common ICU Complication Impacting Patient Recovery
Delirium is an acute brain dysfunction characterized by cognitive decline, confusion, disorientation, and altered behavior. It manifests in three types: hypoactive (withdrawn), mixed, and hyperactive (aggressive). According to Patrys' latest update, delirium affects a large portion of hospitalized patients, especially in intensive care units where rapid intervention is vital to improve outcomes and shorten hospital stays.
Beyond immediate hospital care, delirium increases the risk of later dementia. Up to 80% of ICU patients experience delirium during admission, making it one of the most frequent ICU complications. The high prevalence and serious long-term neurological effects highlight delirium treatment as a critical healthcare challenge and opportunity. Currently, no approved drugs specifically target delirium, leading to off-label use of antipsychotics and benzodiazepines, which results in inconsistent outcomes and safety concerns.
Treatment Limitations: Challenges with Current Off-Label Medications
Patrys notes the absence of approved delirium drugs forces clinicians to rely on off-label options such as haloperidol, risperidone, dexmedetomidine, benzodiazepines, and sedatives. These treatments vary in effectiveness, are supported by limited quality data, and often have significant side effects. Quetiapine, accounting for 47% of antipsychotic use in delirium, is only available orally.
Oral quetiapine's slow onset of 1–2 hours is problematic in acute ICU settings where rapid agitation control is essential. Administering oral drugs to delirious patients is difficult due to their confusion and potential aggression. Despite these challenges, oral quetiapine shows better safety profiles compared to haloperidol and risperidone. This gap between efficacy and delivery underscores the need for an injectable formulation.
Patrys’ Injectable Quetiapine: Enhanced Action and Clinical Advantages
The proprietary injectable quetiapine developed by Patrys aims to provide immediate onset suitable for ICU, palliative, and aged care settings. This formulation facilitates rapid control of agitation, quicker delirium resolution, and improved safety for patients and healthcare workers. Intravenous dosing reduces exposure to norquetiapine (NQTP), the active metabolite linked to side effects such as sedation, anticholinergic effects, and weight gain.
Quetiapine’s mechanism involves weak and transient dopamine D2 antagonism, partial 5-HT1A antagonism, and potent H1 and muscarinic receptor antagonism. These actions reduce agitation, nightmares, extrapyramidal symptoms, and psychosis while enhancing cognition, sleep, anxiety relief, and mood stabilization. Additionally, quetiapine offers neuroprotection through BDNF pathways and anti-inflammatory effects by lowering IL-1β, IL-6, and TNF-α. IV administration minimizes metabolite-related side effects while preserving therapeutic benefits.
Regulatory Strategy and Development Timeline: Accelerated FDA Approval Pathway
Patrys intends to use the FDA 505(b)(2) pathway, leveraging existing safety and efficacy data for quetiapine. This pathway allows reliance on published data for the active ingredient, reducing the need for extensive new trials.
The development timeline is estimated at 3–5 years with costs between US$20 million and US$30 million, substantially shorter and less costly than the 10–15 years and approximately US$1.2 billion required for new drug discovery. This approach lowers financial risk and enables earlier commercialization potential.
Market Potential: Over US$2 Billion Annual Opportunity in Delirium Treatment
The addressable market for delirium treatment exceeds US$2 billion globally, reflecting high delirium prevalence in ICU, hospital, aged care, and palliative settings, alongside the lack of approved drugs and reliance on off-label antipsychotics. Approval of a dedicated delirium drug could capture significant market share.
Delirium affects up to 80% of ICU patients and is also common post-operation, in general wards, aged care, and palliative care. Patrys targets ICU, palliative, and aged care sectors, covering multiple revenue streams and regions. Being first-to-market with an FDA-approved delirium drug would provide a strong competitive advantage.
Intellectual Property: Strong Patent Protection for Injectable Formulation
Patrys holds Australian provisional patent (No. 2022901032) fully owned without trailing obligations, extending protection to around 2042. A new provisional patent application was filed in 2026 for additional intellectual property related to the reformulated product.
The patent strategy focuses on the formulation, delivery method, and manufacturing process rather than the active drug. Full ownership without royalties or licensing restrictions enhances commercial value and control over licensing and commercialization.
Experienced Leadership: Board Expertise in Biotech and ASX Commercialisation
The board includes Chairman Peter Christie with 25+ years in ASX governance, currently chairing ASX:MOH and directing ASX:MRD. Director Leanne Kite brings 20+ years in capital markets and investor relations, including experience with ASX 200 lithium producer Liontown Resources. Director Dino Cercarelli is COO of the Australian Clinical Trials Alliance with clinical trial operations expertise.
Director Brian Leedman is a biotech entrepreneur with a strong ASX healthcare record, co-founder of ResApp Health (acquired by Pfizer), and chairs or directs multiple ASX-listed healthcare companies. Director Dr Anton Uvarov is a healthcare investment specialist and co-founder of several ASX-listed biotech firms. CEO Dr Samantha South has extensive CNS research experience and over 15 years in medtech and biotech commercialization. This leadership team combines biotech development, ASX governance, and capital market expertise.
Clinical Evidence Foundation: Leveraging Established Quetiapine Data
Patrys’ strategy relies on quetiapine’s well-established clinical safety and efficacy, accumulated over decades of use. This extensive data supports the FDA 505(b)(2) pathway by demonstrating that the injectable formulation maintains the original drug’s therapeutic profile.
Quetiapine is an FDA-approved atypical antipsychotic widely prescribed in psychiatric, geriatric, and acute care. Patrys needs only to prove bioavailability and safety of the injectable form without repeating full clinical trials, significantly reducing development time and cost compared to novel antipsychotics.
Competitive Edge and Market Entry: Addressing Unmet Needs in Delirium Care
Patrys targets a market with no approved delirium drugs and significant unmet medical needs. Their injectable quetiapine overcomes oral formulation limitations by enabling rapid symptom control in agitated delirium patients, positioning the company to capture market share from off-label treatments while improving clinical outcomes.
Quetiapine’s favorable safety profile compared to haloperidol and risperidone, combined with the injectable form’s ease of administration, offers a distinct advantage. The 3–5 year development timeline and moderate costs provide financial flexibility for potential label expansions into other acute agitation indications across psychiatric and emergency care.
Upcoming Milestones: Key Development and Regulatory Events for Investors
Investors should watch for clinical study initiations, FDA pre-submission meetings, and formulation development progress within the 3–5 year timeline. The provisional patents filed in Australia and new 2026 filings indicate ongoing innovation.
Further milestones include FDA regulatory interactions to confirm the 505(b)(2) pathway, clinical trial design and recruitment, study completion, and regulatory submission. Given quetiapine’s safety profile, clinical trials may focus on pharmacokinetics, bioavailability, and safety/efficacy confirmation rather than extensive efficacy testing. Potential partnerships or licensing deals with pharmaceutical or hospital groups could add value before commercialization.
